PHARMACEUTICAL COMPOSITIONS OF IBUPROFEN AND AN H2 RECEPTOR ANTAGONIST
Pharmaceutical compositions of a H 2 receptor antagonist and ibuprofen are provided herein. The compositions comprise, e.g., a core and a shell separated by a barrier layer, bilayered or trilayered compositions, or liquid formulations. Also provided are methods of making the pharmaceutical compositions, and methods of treatment comprising administering the pharmaceutical compositions. Also provided is a method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which a pharmaceutical composition comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of an H 2 RA, such as famotidine, is administered three times per day
1 .- 43 . (canceled)
44 . A pharmaceutical composition having a bilayer architecture comprising:
a first layer comprising famotidine and further comprising hypromellose (hydroxypropylmethylcellulose), and
a second layer comprising ibuprofen,
wherein the pharmaceutical composition is suitable for three times per day (TID) administration, and
wherein both the famotidine and ibuprofen are formulated for immediate release at about the same time.
45 . The pharmaceutical composition of claim 44 , wherein the pharmaceutical composition comprises about 24 mg to about 28 mg famotidine.
46 . The pharmaceutical composition of claim 44 , wherein the pharmaceutical composition comprises about 750 mg to about 850 mg ibuprofen.
47 . The pharmaceutical composition of claim 44 , wherein the first layer further comprises at least one lubricant.
48 . The pharmaceutical composition of claim 47 , wherein the at least one lubricant is magnesium stearate.
49 . The pharmaceutical composition of claim 44 , wherein the first layer further comprises at least one binder other than hypromellose (hydroxypropylmethylcellulose).
50 . The pharmaceutical composition of claim 49 , wherein the at least one binder is microcrystalline cellulose.
51 . The pharmaceutical composition of claim 44 , wherein the first layer further comprises at least one glidant.
52 . The pharmaceutical composition of claim 51 , wherein the at least one glidant is colloidal silicon dioxide.
53 . The pharmaceutical composition of claim 44 , wherein the first layer comprises famotidine, magnesium stearate, microcrystalline cellulose, hypromellose, and colloidal silicon dioxide.
54 . The pharmaceutical composition of claim 44 , wherein the second layer further comprises at least one binder.
55 . The pharmaceutical composition of claim 54 , wherein the at least one binder is microcrystalline cellulose.
56 . The pharmaceutical composition of claim 55 , wherein the second layer comprises at least one binder other than microcrystalline cellulose.
57 . The pharmaceutical composition of claim 56 , wherein the at least one binder other than microcrystalline cellulose is chosen from Klucel EXF hydroxypropyl cellulose, propylene glycol, Starch 1500, Lubritab, Kollidon VA 64 vinylpyrrolidone-vinyl acetate copolymer, PVP K 30 polyvinyl pyrrolidone, sodium stearyl fumarate, and stearic acid.
58 . The pharmaceutical composition of claim 56 , wherein at least one binder other than microcrystalline cellulose is hypromellose (hydroxypropylmethylcellulose).
59 . The pharmaceutical composition of claim 44 , wherein the second layer further comprises at least one lubricant.
60 . The pharmaceutical composition of claim 59 , wherein the at least one lubricant is sodium stearyl fumarate.
61 . The pharmaceutical composition of claim 44 , wherein the second layer further comprises at least one glidant.
62 . The pharmaceutical composition of claim 61 , wherein the at least one glidant is colloidal silicon dioxide.
63 . The pharmaceutical composition of claim 44 , wherein the second layer further comprises at least one disintegrant.
64 . The pharmaceutical composition of claim 63 , wherein at least one disintegrant is croscarmellose sodium.
65 . The pharmaceutical composition of claim 44 , wherein the second layer comprises ibuprofen, microcrystalline cellulose, sodium stearyl fumarate, colloidal silicon dioxide, hypromellose, and croscarmellose sodium.
66 . The pharmaceutical composition of claim 53 , wherein the second layer comprises ibuprofen, microcrystalline cellulose, sodium stearyl fumarate, colloidal silicon dioxide, hypromellose, and croscarmellose sodium.
67 . The pharmaceutical composition of claim 44 , wherein the first layer and the second layer are separated by a barrier layer.
68 . A pharmaceutical composition having a trilayer architecture comprising
a first layer comprising a therapeutically effective amount of famotidine,
a second layer comprising ibuprofen, and
a third layer comprising ibuprofen,
wherein the first layer is adjacent to a first side of the second layer, and the third layer is adjacent to a second side of the first layer,
wherein the total amount of ibuprofen in the pharmaceutical composition is a therapeutically effective amount,
wherein the pharmaceutical composition is suitable for three times per day (TID) administration, and
wherein both the famotidine and ibuprofen are formulated for immediate release at about the same time.
69 . The pharmaceutical composition of claim 68 , wherein the first layer and the second layer are separated by a first barrier layer, and the first layer and the third layer are separated by a second barrier layer.
70 . The pharmaceutical composition of claim 68 , wherein the first barrier layer is the same, both in amount and content, as the second barrier layer.
71 . The pharmaceutical composition of claim 68 , wherein the first barrier layer is different, either in amount and/or content, from the second barrier layer.
72 . A pharmaceutical composition comprising:
a first compartment comprising
a therapeutically effective amount of famotidine;
from about 42 mg to about 46 mg of microcrystalline cellulose;
from about 10 mg to about 19 mg of at least one binder other than microcrystalline cellulose; and
from about 0.9 mg to about 1.9 mg of at least one lubricant, and
a second compartment comprising
a therapeutically effective amount of ibuprofen;
from about 200 to about 250 mg of at least one binder; and
from about 2.5 mg to about 3.5 mg of at least one lubricant,
wherein said first compartment is separated from said second compartment.
73 . A method for method for reducing the risk of developing ibuprofen-induced ulcers in a human patient requiring ibuprofen for an ibuprofen-responsive condition, said method comprising:
administering to the human patient a first dose of famotidine,
administering to the human patient a second dose of famotidine, and
administering to the human patient a third dose of famotidine, and
wherein for each administration, the famotidine is administered as a pharmaceutical composition of claim 44 .